Vistagen Clears FDA Hurdle for Phase 2 Trial of Non-Hormonal Menopause Treatment
Event summary
- Vistagen received FDA 'Study May Proceed' letter for refisolone nasal spray IND application, enabling Phase 2 trials for menopausal hot flashes.
- Refisolone showed 80% reduction in hot flash frequency in exploratory Phase 2a study vs. 36% for placebo.
- Non-hormonal, non-systemic treatment targets 75% of American women experiencing menopausal hot flashes.
- Phase 2a study conducted in Mexico by subsidiary Pherin Pharmaceuticals demonstrated rapid onset of effect within one week.
The big picture
Vistagen's FDA clearance positions refisolone as a potential disruptor in the $3 billion menopause treatment market, where current options are limited by hormonal side effects. The company's nose-to-brain delivery technology represents a novel approach to neurocircuitry-focused treatments, aligning with broader industry trends toward targeted, non-systemic therapies. Success could validate Vistagen's pherine platform across multiple indications, including anxiety and depression.
What we're watching
- Clinical Efficacy
- Whether refisolone can replicate Phase 2a results in larger U.S. trials and demonstrate sustained efficacy.
- Regulatory Pathway
- The pace at which Vistagen advances through Phase 2 and potential accelerated approval pathways for menopause treatments.
- Market Differentiation
- How Vistagen positions refisolone against existing hormonal and non-hormonal therapies in a competitive women's health market.
Related topics